Cargando…

Fuzuloparib: First Approval

Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment...

Descripción completa

Detalles Bibliográficos
Autor principal: Lee, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380563/
https://www.ncbi.nlm.nih.gov/pubmed/34118019
http://dx.doi.org/10.1007/s40265-021-01541-x
_version_ 1783741221617795072
author Lee, Arnold
author_facet Lee, Arnold
author_sort Lee, Arnold
collection PubMed
description Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs. This article summarizes the milestones in the development of fuzuloparib leading to this first approval for the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer in patients with germline BRCA mutation who have undergone second-line or above chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-021-01541-x.
format Online
Article
Text
id pubmed-8380563
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83805632021-09-08 Fuzuloparib: First Approval Lee, Arnold Drugs AdisInsight Report Fuzuloparib (AiRuiYi(®), 艾瑞颐; formerly fluzoparib) is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (formerly Jiangsu Hengrui Medicine Co., Ltd.) for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs. This article summarizes the milestones in the development of fuzuloparib leading to this first approval for the treatment of platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer in patients with germline BRCA mutation who have undergone second-line or above chemotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-021-01541-x. Springer International Publishing 2021-06-12 2021 /pmc/articles/PMC8380563/ /pubmed/34118019 http://dx.doi.org/10.1007/s40265-021-01541-x Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Lee, Arnold
Fuzuloparib: First Approval
title Fuzuloparib: First Approval
title_full Fuzuloparib: First Approval
title_fullStr Fuzuloparib: First Approval
title_full_unstemmed Fuzuloparib: First Approval
title_short Fuzuloparib: First Approval
title_sort fuzuloparib: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380563/
https://www.ncbi.nlm.nih.gov/pubmed/34118019
http://dx.doi.org/10.1007/s40265-021-01541-x
work_keys_str_mv AT leearnold fuzuloparibfirstapproval